Q2 2026 Mendus AB (publ) Earnings Call Transcript
Key Points
- ADVANCE-II trial reached final stage with majority of patients achieving five-year survival, validating the product's long-term efficacy in AML.
- CADENCE trial met its 20-patient enrollment milestone ahead of schedule, with no product-related serious adverse events, confirming a strong safety profile.
- Expansion into pediatric AML and CML programs diversifies the pipeline and addresses high unmet medical needs, potentially opening faster paths to market.
- Initiation of US analyst coverage by Lucid Capital Markets increases visibility and access to US investors, supporting future financing efforts.
- Successful preparation of the DIVA trial in the Venetoclax/azacitidine setting broadens the product's positioning in first-line AML treatment, with initial readouts expected in Q1 2027.
- Cash position of SEK59.9 million only funds operations into Q1 2027, necessitating additional financing to support the expanded clinical pipeline.
- The VITAL-TFR2 trial's start is contingent on a positive safety readout from VITAL-CML, creating dependency on interim results.
- The DIVA trial's initiation is pending final ethics committee approval, introducing potential delays to the planned Q3 2026 start.
- The pediatric AML program is subject to financing, and the company's ability to execute all planned trials is dependent on securing adequate funding.
- The CADENCE trial's initial readout may lack clear efficacy signals due to the inclusion of MRD-negative patients, making early data interpretation more complex.
(audio in progress) 2026 reports presentation. We will begin with the presentation from the company speakers, CEO, Dr. Erik Manting; and CFO, Lotta Ferm. (Operator Instructions) I will now hand over to CEO, Dr. Erik Manting. Please go ahead.
()-
Thank you, and welcome, everybody, on behalf of myself and Lotta.
()-
Hello, everyone. Nice to meet you.
()-
Thanks for joining Mendus' financial and business update over the second quarter of 2026. It was a very busy quarter in which the clinical development gained a lot of momentum. We have reached the final stage of the ADVANCE-II trial. The long-term follow-up of the trial is officially concluding when the last patient has reached the five-year mark, and we're happy to disclose
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
